EMA Makes Progress On Real-World Evidence ‘Use Cases’ With HTA Bodies & Payers

The European Medicines Agency is looking at how it can generate real-world evidence on multiple myeloma and non-small cell lung cancer using its new DARWIN EU platform so that the outcomes can also be of use for health technology assessment bodies and payers.

Patient data
RWE can complement the evidence generated by randomized controlled clinical trials • Source: Shutterstock

The European Medicines Agency is exploring the feasibility of running two real-world evidence studies that could be of use to health technology assessment (HTA) bodies and payers as well as the agency in their respective areas of decision-making.

The first study will look at the natural history of multiple myeloma, while the second will focus on non-small cell...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography